Pathophysiology
Mechanisms of Dry Eye Syndrome (DES)
Several factors contribute to the development of DES, including:
- Lacrimal, meibomian and accessory gland function
- Goblet cell function
- Ocular surface and eyelid health and anatomy
- Inflammation in the tear film
- Hormonal abnormalities.
The core mechanism and hallmark feature of DES pathogenesis is tear film hyperosmolarity. Both aqueous tear deficient dry eye (ADDE) and EDE involve tear hyperosmolarity: in ADDE, it occurs because less solvent (water) is produced by the lacrimal glands and in evaporative dry eye (EDE) because too much water is lost by evaporation. The hyperosmolarity causes both direct and indirect (i.e., inflammatory) damage to the ocular surface, particularly to epithelial and goblet cells. This activates epithelial stress signaling, mediated by mitogen activated protein kinase (MAPK) and nuclear factor κB (NFκB), which in turn stimulates release of pro-inflammatory factors, including cytokines (e.g., IL-1), tumor necrosis…
To continue reading
Log in or register to continue reading. It's free!
OR
By signing up to create an account, I accept Healio's Terms of Use and Privacy Policy.
Mechanisms of Dry Eye Syndrome (DES)
Several factors contribute to the development of DES, including:
- Lacrimal, meibomian and accessory gland function
- Goblet cell function
- Ocular surface and eyelid health and anatomy
- Inflammation in the tear film
- Hormonal abnormalities.
The core mechanism and hallmark feature of DES pathogenesis is tear film hyperosmolarity. Both aqueous tear deficient dry eye (ADDE) and EDE involve tear hyperosmolarity: in ADDE, it occurs because less solvent (water) is produced by the lacrimal glands and in evaporative dry eye (EDE) because too much water is lost by evaporation. The hyperosmolarity causes both direct and indirect (i.e., inflammatory) damage to the ocular surface, particularly to epithelial and goblet cells. This activates epithelial stress signaling, mediated by mitogen activated protein kinase (MAPK) and nuclear factor κB (NFκB), which in turn stimulates release of pro-inflammatory factors, including cytokines (e.g., IL-1), tumor necrosis factor α (TNFα) and matrix metalloproteases (MMPs). Inflammation of the ocular surface also disrupts the neuronal pathways that control blink rate, tearing and corneal sensation. Epithelial and neuronal disruption promotes further tear film instability and sets up a self-perpetuating positive feedback loop. The core and ancillary mechanisms contributing to DES are shown in Figure 1-3.
It is important to note that tear film instability can start in the absence of hyperosmolarity. For example, conditions such as xerophthalmia, ocular allergy and topical preservative and contact lens use, may cause early tear film breakup, leading to local hyperosmolarity and initiating the inflammatory cascade downstream. This is an example of ocular surface-related EDE.
Finally, in line with the recognition that manifestations of DES fall on a spectrum between ADDE and EDE, it is important to keep in mind that multiple mechanisms may coexist and produce similar symptoms. This is illustrated in Figure 1-4, which shows that the four DES categories defined by CEDARS may have overlapping symptoms.
References
- Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438-510.
- Chan C. Dry Eye : A Practical Approach. Springer; 2015.
- Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II Report Executive Summary. Ocul Surf. 2017;15(4):802-812.
- Dana R, Bradley JL, Guerin A, et al. Estimated Prevalence and Incidence of Dry Eye Disease Based on Coding Analysis of a Large, All-age United States Health Care System. Am J Ophthalmol. 2019;202:47-54.
- Golden MI, Meyer JJ, Zeppieri M, et al. Dry Eye Syndrome. [Updated 2024 Feb 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470411/
- Gomes JAP, Azar DT, Baudouin C, et al. TFOS DEWS II iatrogenic report. Ocul Surf. 2017;15(3):511-538.
- Hakim FE, Farooq AV. Dry Eye Disease: An Update in 2022. JAMA. 2022;327(5):478-479.
- Huang R, Su C, Fang L, Lu J, Chen J, Ding Y. Dry eye syndrome: comprehensive etiologies and recent clinical trials. Int Ophthalmol. 2022;42(10):3253-3272.
- Kawashima M, Yamada M, Shigeyasu C, et al. Association of Systemic Comorbidities with Dry Eye Disease. J Clin Med. 2020;9(7):2040.
- Mah F, Rhee MK, eds. Dry Eye Disease : A Practical Guide. Slack Incorporated; 2019.
- McCann P, Abraham AG, Mukhopadhyay A, et al. Prevalence and Incidence of Dry Eye and Meibomian Gland Dysfunction in the United States: A Systematic Review and Meta-analysis. JAMA Ophthalmol. 2022;140(12):1181-1192.
- Milner MS, Beckman KA, Luchs JI, et al. Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment. Curr Opin Ophthalmol. 2017;27 Suppl 1(Suppl 1):3-47.
- Mondal H, Kim HJ, Mohanto N, Jee JP. A Review on Dry Eye Disease Treatment: Recent Progress, Diagnostics, and Future Perspectives. Pharmaceutics. 2023;15(3):990.
- Papas EB. The global prevalence of dry eye disease: A Bayesian view. Ophthalmic Physiol Opt. 2021;41(6):1254-1266.
- Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II Epidemiology Report. Ocul Surf. 2017;15(3):334-365.